Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

[1]  L. Tombs,et al.  Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis , 2019, Respiratory Research.

[2]  L. Tombs,et al.  Long-term outcomes following first short-term clinically important deterioration in COPD , 2018, Respiratory Research.

[3]  A. Ismaila,et al.  Preventing clinically important deterioration with single-inhaler triple therapy in COPD , 2018, ERJ Open Research.

[4]  L. Tombs,et al.  Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis , 2018, Advances in Therapy.

[5]  J. Wedzicha,et al.  Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study , 2018, Respiratory Research.

[6]  J. Wedzicha,et al.  Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. , 2018, The Lancet. Respiratory medicine.

[7]  P. Jones,et al.  Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. , 2018, Pulmonary pharmacology & therapeutics.

[8]  E. Horváth-Puhó,et al.  Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. , 2018, The Lancet. Respiratory medicine.

[9]  A. Ismaila,et al.  A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD , 2017, Pulmonary Therapy.

[10]  A. Anzueto,et al.  The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD , 2017, International journal of chronic obstructive pulmonary disease.

[11]  A. Anzueto,et al.  Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials , 2016, Advances in Therapy.

[12]  Dave Singh,et al.  Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol , 2016, International journal of chronic obstructive pulmonary disease.

[13]  M. Cazzola,et al.  A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.

[14]  F. Maltais,et al.  A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD , 2016, International journal of chronic obstructive pulmonary disease.

[15]  Dave Singh,et al.  Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. , 2016, Respiratory medicine.

[16]  S. Dias,et al.  Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis , 2015, Thorax.

[17]  N. Leidy,et al.  Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials , 2014, Respiratory Research.

[18]  E. Kerwin,et al.  Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[19]  B. Celli,et al.  Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. , 2014, Chest.

[20]  S. Kon,et al.  Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.

[21]  A. Church,et al.  Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. , 2013, Respiratory medicine.

[22]  L. Edwards,et al.  Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort , 2013, European Respiratory Journal.

[23]  E. Bateman,et al.  Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study , 2013, European Respiratory Journal.

[24]  J. Wedzicha,et al.  Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[25]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[26]  J. Wedzicha,et al.  Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. , 2012, American journal of respiratory and critical care medicine.

[27]  W. Bailey,et al.  Disease severity and symptoms among patients receiving monotherapy for COPD. , 2010, Primary care respiratory journal : journal of the General Practice Airways Group.

[28]  D. Mahler,et al.  The MCID of the Transition Dyspnea Index is a Total Score of One Unit , 2005, COPD.

[29]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[30]  P. Jones.  Interpreting thresholds for a clinically significant change in health status in asthma and COPD , 2002, European Respiratory Journal.